Bemfivastatin

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C34H37FN2O6
Molecular Weight	588.6658
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=C(C(=O)NC2=CC=C(CO)C=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C3=CC=C(F)C=C3)C4=CC=CC=C4

InChI

InChIKey=PMFRPLBQEYHUMG-VSGBNLITSA-N

InChI=1S/C34H37FN2O6/c1-21(2)32-31(34(43)36-26-14-8-22(20-38)9-15-26)30(23-6-4-3-5-7-23)33(24-10-12-25(35)13-11-24)37(32)17-16-27(39)18-28(40)19-29(41)42/h3-15,21,27-28,38-40H,16-20H2,1-2H3,(H,36,43)(H,41,42)/t27-,28-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C34H37FN2O6
Molecular Weight	588.6658
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:32:29 GMT 2023` Edited by `admin` on `Sat Dec 16 11:32:29 GMT 2023`
Record UNII	F47K281Y9S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Bemfivastatin

Official Name

English

1H-PYRROLE-1-HEPTANOIC ACID, 2-(4-FLUOROPHENYL)-.BETA.,.DELTA.-DIHYDROXY-4-(((4-(HYDROXYMETHYL)PHENYL)AMINO)CARBONYL)-5-(1-METHYLETHYL)-3-PHENYL-, (.BETA.R,.DELTA.R)-

Systematic Name

English

PPD10558

Code

English

PPD-10558

Code

English

bemfivastatin [INN]

Common Name

English

RBX-10558

Code

English

(3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-(((4-HYDROXYMETHYLPHENYL)AMINO)CARBONYL)PYRROL-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID

Systematic Name

English

Code System Code Type Description

FDA UNII

F47K281Y9S

Created by admin on Sat Dec 16 11:32:29 GMT 2023 , Edited by admin on Sat Dec 16 11:32:29 GMT 2023

PRIMARY

CAS

805241-79-6

Created by admin on Sat Dec 16 11:32:29 GMT 2023 , Edited by admin on Sat Dec 16 11:32:29 GMT 2023

PRIMARY

PUBCHEM

11192585

Created by admin on Sat Dec 16 11:32:29 GMT 2023 , Edited by admin on Sat Dec 16 11:32:29 GMT 2023

PRIMARY

INN

12520

Created by admin on Sat Dec 16 11:32:29 GMT 2023 , Edited by admin on Sat Dec 16 11:32:29 GMT 2023

PRIMARY

Related Record Type Details


					3I8G750MW3

Bemfivastatin calcium

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					F47K281Y9S

Bemfivastatin

ACTIVE MOIETY

Comments:

Class: Antihyperlipidaemic; Mechanism of Action: HMG-CoA reductase inhibitor; Highest Development Phase: Discontinued for Hypercholesterolaemia; Most Recent Events: 08 Dec 2011 Discontinued - Phase-II for Hypercholesterolaemia in USA (PO),23 Mar 2011 Phase-IIb clinical trials in Hypercholesterolaemia (with history of statin-associated myalgia) in USA (PO), 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo

Amount:


					F47K281Y9S

Bemfivastatin

ACTIVE MOIETY

Comments:

PPD10558 is an orally active, lipid-lowering 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) being developed as a treatment for hypercholesterolemia in patients who have not been able to tolerate statins because of statin-associated myalgia. In rabbits, marked maternal toxicity including mortality (eight deaths 1 dose at 25 and 7 at 50 mg/kg/day), abortions (2 at 25 mg/kg/day and 6 at 50 mg/kg/day) and reduction in gestation body weight, gestation body weight changes and decreased food consumption were observed. In addition, fetal body weights of the combined sexes were significantly reduced at 50 mg/kg/day in comparison with the controls. Mean peak exposure (Cmax) and total exposure (AUC(0-24)) of PPD11901 in both rats and rabbits were higher than that of PPD10558 on GD 6 and GD 17 at each of the three dose levels.. Based on the results of these studies, the no observed adverse effect level (NOAEL) for maternal and developmental toxicity in rats was considered to be 320 mg/kg/day, the highest dose level used in the study. The NOAEL for maternal and developmental toxicity in rabbits was 12.5 mg/kg/day and 25 mg/kg/day, respectively.

Amount: